Check out your Company Bowl for anonymous work chats.
We're proud to announce that our Suzhou, China laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification. This achievement marks our second CLIA certification in 2025, following our San Diego facility earlier this year, underscoring Crown Bioscience’s continued commitment to expanding its global network of compliant, clinical-grade laboratories.
We’re incredibly proud to announce that Crown Bioscience has been named Best Preclinical Oncology CRO 2025 in the Healthcare and Pharmaceutical Awards by Global Health & Pharma (GHP) Magazine. Recognized for our outstanding contributions to preclinical oncology research & our comprehensive portfolio of translational platforms that help biopharmaceutical partners accelerate drug discovery and development, we’re setting new standards in translational science.
We are thrilled to announce the opening of our state-of-the-art model development center in Kannapolis, North Carolina – strengthening our operations and enhancing our ability to deliver advanced preclinical oncology models to meet the evolving needs of pharma and biotech companies. The Kannapolis facility reinforces our US-based capabilities and is aligned with our broader strategy to provide localized access to global scientific expertise and top-quality preclinical services. The new site will support drug screening, indication selection, and combination therapy strategies, while accelerating the adoption of 3D cell culture and organoid technologies in response to key industry developments.
Medicines Discovery Catapult (MDC) and Crown Bioscience have formed a strategic global collaboration to deliver an integrated translational biology platform for innovators developing radiopharmaceuticals. The collaboration enables rapid and reliable testing of how radiopharmaceuticals work, how the body responds to them, and how effective they are – all critical factors in identifying viable drug candidates early and reducing clinical development risk. Together, MDC and Crown Bioscience provide a fully integrated preclinical workflow for companies developing radiotherapeutics. Read the press release here:
We are incredibly proud to announce that our San Diego laboratory has received Clinical Laboratory Improvement Amendments (CLIA) certification, marking a crucial step in our commitment to delivering high-quality, compliant laboratory services. As a CLIA-certified lab, we’re now equipped to conduct clinical testing on human specimens – a key component of advancing oncology research and personalized medicine. With rigorous federal standards for accuracy, reliability, and quality laboratory operations, this designation strengthens our position as a trusted partner capable of meeting specialized project needs throughout all stages of drug development. Learn more: https://www.crownbio.com/about-us/news-and-events/crown-bioscience-san-diego-achieves-clia-certification-to-enhance-clinical-trial-support
We are delighted to announce the promotion of Alex Slater to Chief Business Officer, reinforcing the company’s commitment to advancing commercial excellence and client-centric growth. Alex Slater has been with Crown Bioscience since 2021, most recently serving as Senior Vice President of Commercial, where he played a pivotal role in driving the company’s commercial strategy across APAC, EMEA, and the US. Throughout his tenure, Alex has led the business development function, helping to expand Crown Bioscience’s market presence and deliver innovative solutions to clients worldwide. Learn More: https://www.crownbio.com/about-us/news-and-events/crown-bioscience-announces-promotion-of-alex-slater-to-chief-business-officer-signaling-continued-focus-on-commercial-excellence
We are thrilled to reveal that Fierce Biotech has named Crown Bioscience as the ‘Fierce CRO Award winner’ in the ‘Excellence in Global Operations’ category. Fierce CRO Award finalists and winners are evaluated based on: • Innovation and Impact • Measurable Outcomes • Sustainability and Scalability • Ethical and Regulatory Adherence We are proud of our global teams in continuing to deliver operational excellence around the world! https://www.fiercebiotech.com/cro/excellence-global-operations
We are delighted to announce that our facility in Leiden, Netherlands, has achieved the highest level of certification in the My Green Lab Certification program. This ‘Green’ level certification is the gold standard in laboratory sustainability best practices. After a thorough assessment, the lab earned a score of 81% – the highest level possible – evidencing excellence and leadership in eco-friendly laboratory management. As a clear demonstration that environmental responsibility and world-class oncology research go hand in hand, we’re now committed to expanding our sustainable lab practices to all locations worldwide.
We're pleased to announce the extension of our partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. This strategic partnership will continue to leverage our extensive experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models, together with NEXT Oncology's global clinical network and Phase I clinical trials expertise. This collaboration underscores our commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research. Read more: https://www.crownbio.com/about-us/news-and-events/crown-bioscience-and-next-oncology-cement-partnership-extension
We are proud to unveil at AACR 2025 our cutting-edge 3D bone marrow niche (BMN) in vitro models to advance hematological cancer research. Providing both the physical environment (cell-cell interactions), and the growth factor cocktail that hematological cancer cells require to thrive and proliferate, this innovative model provides a dynamic platform for studying liquid malignancies such as acute myeloid leukemia (AML) and multiple myeloma (MM). The introduction of the BMN platform seamlessly integrates into our expertise in 3D organoid-like cell cultures, drug resistance models, and AML mouse models and bridges a gap between in vitro and in vivo models. Read more about this cutting-edge platform: https://www.crownbio.com/about-us/news-and-events/aacr-2025-crown-bioscience-unveils-3d-bone-marrow-niche-in-vitro-models-for-oncology-preclinical-screening-in-hematological-malignancies
